CA2510787A1 - Pharmaceutical compositions having an effect on the proliferation of nk cells and a method using the same - Google Patents

Pharmaceutical compositions having an effect on the proliferation of nk cells and a method using the same Download PDF

Info

Publication number
CA2510787A1
CA2510787A1 CA002510787A CA2510787A CA2510787A1 CA 2510787 A1 CA2510787 A1 CA 2510787A1 CA 002510787 A CA002510787 A CA 002510787A CA 2510787 A CA2510787 A CA 2510787A CA 2510787 A1 CA2510787 A1 CA 2510787A1
Authority
CA
Canada
Prior art keywords
cells
antibody
pharmaceutical compositions
antibodies
nkp30
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002510787A
Other languages
English (en)
French (fr)
Inventor
Francois Romagne
Pascale Andre
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innate Pharma SA
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2510787A1 publication Critical patent/CA2510787A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002510787A 2002-12-23 2003-12-22 Pharmaceutical compositions having an effect on the proliferation of nk cells and a method using the same Abandoned CA2510787A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43534402P 2002-12-23 2002-12-23
US60/435,344 2002-12-23
PCT/EP2003/014716 WO2004056392A1 (en) 2002-12-23 2003-12-22 Pharmaceutical compositions having an effect on the proliferation of nk cells and a method using the same

Publications (1)

Publication Number Publication Date
CA2510787A1 true CA2510787A1 (en) 2004-07-08

Family

ID=32682222

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002510787A Abandoned CA2510787A1 (en) 2002-12-23 2003-12-22 Pharmaceutical compositions having an effect on the proliferation of nk cells and a method using the same

Country Status (6)

Country Link
US (1) US20080063717A1 (https=)
EP (1) EP1575615A1 (https=)
JP (1) JP2006514024A (https=)
AU (1) AU2003294930B2 (https=)
CA (1) CA2510787A1 (https=)
WO (1) WO2004056392A1 (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6307024B1 (en) 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
HRP20170342T1 (hr) * 2003-07-24 2017-05-19 Innate Pharma S.A. Metode i sastavi za povećanje učinkovitosti terapijskih protutijela koristeći tvari koje potenciraju nk stanice
US20070178106A1 (en) * 2004-04-30 2007-08-02 Innate Pharma, S.A. Compositions and methods for enhancing nk cell activity
US20090196850A1 (en) * 2005-01-06 2009-08-06 Novo Nordisk A/S Anti-Kir Combination Treatments and Methods
WO2007111714A2 (en) 2005-11-28 2007-10-04 Zymogenetics, Inc. Il-21 antagonists
US7883700B2 (en) 2007-12-07 2011-02-08 Zymogenetics, Inc. Anti-human IL-21 monoclonal antibodies
KR101133185B1 (ko) * 2008-07-29 2012-04-06 서울대학교병원 자연살해세포의 증식방법
ES2765874T3 (es) 2011-05-25 2020-06-11 Innate Pharma Sa Anticuerpos anti-KIR para el tratamiento de trastornos inflamatorios
JP5572863B2 (ja) * 2011-06-24 2014-08-20 国立大学法人九州大学 Ｎｋ細胞の増幅方法
JP5997296B2 (ja) 2013-01-15 2016-09-28 阿部　博幸 免疫細胞含有組成物の製造方法及び癌治療用組成物
EP2824112B1 (en) 2013-07-10 2016-12-21 Miltenyi Biotec GmbH Method for inducing proliferation of Natural Killer cells by mobile nanomatrices
CN105462923B (zh) * 2014-12-17 2018-11-02 山东大学第二医院 一种人自然杀伤细胞体外高效扩增方法
JP6073417B2 (ja) * 2015-06-26 2017-02-01 チャ バイオテック カンパニー リミテッド 自然殺害細胞増殖方法、及び自然殺害細胞増殖用の組成物
US10786547B2 (en) 2015-07-16 2020-09-29 Biokine Therapeutics Ltd. Compositions, articles of manufacture and methods for treating cancer
US10736963B2 (en) 2015-07-24 2020-08-11 Innate Pharma Methods for detecting tissue infiltrating NK cells
EP3397645B1 (en) * 2015-12-28 2026-03-25 Innate Pharma Variable regions for nkp46 binding proteins
WO2017165464A1 (en) 2016-03-21 2017-09-28 Elstar Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
EP3500298A4 (en) * 2016-08-17 2020-04-01 University Health Network REGULATION OF TUMOR ASSOCIATED T CELLS
MY206158A (en) 2017-05-24 2024-12-02 Novartis Ag Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
EP3765517A1 (en) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
CA3105448A1 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
CN111304248B (zh) 2018-12-25 2021-08-24 百奥赛图江苏基因生物技术有限公司 人源化细胞因子il15基因改造非人动物的构建方法及应用
JP7737306B2 (ja) 2019-02-21 2025-09-10 マレンゴ・セラピューティクス，インコーポレーテッド Ｔ細胞に結合する多機能性分子および自己免疫障害を処置するためのその使用
GB2599228B (en) 2019-02-21 2024-02-07 Marengo Therapeutics Inc Multifunctional molecules that bind to T cell related cancer cells and uses thereof
EP3927746A1 (en) 2019-02-21 2021-12-29 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
CN119039441A (zh) * 2019-02-21 2024-11-29 马伦戈治疗公司 与nkp30结合的抗体分子及其用途
EP4084821A4 (en) 2020-01-03 2024-04-24 Marengo Therapeutics, Inc. Multifunctional molecules that bind to cd33 and uses thereof
AU2020416273A1 (en) 2020-01-03 2022-07-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
CA3164182A1 (en) * 2020-01-17 2021-07-22 Liu XUE Anti-nkp30 antibodies and methods of use
CN115843312A (zh) 2020-04-24 2023-03-24 马伦戈治疗公司 结合至t细胞相关癌细胞的多功能性分子及其用途
GB2616354A (en) 2020-08-26 2023-09-06 Marengo Therapeutics Inc Methods of detecting TRBC1 or TRBC2
GB2616128A (en) 2020-08-26 2023-08-30 Marengo Therapeutics Inc Antibody molecules that bind to NKp30 and uses thereof
AU2021331075A1 (en) 2020-08-26 2023-04-06 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
KR102581230B1 (ko) * 2020-10-16 2023-09-21 의료법인 성광의료재단 항암 관련 유전자 발현이 조절된 자연살해세포 및 이의 용도
KR102236011B1 (ko) * 2020-11-11 2021-04-05 한바이오 주식회사 Nk 세포의 대량증식 배양방법
US12345068B2 (en) 2021-11-19 2025-07-01 Sundance Spas, Inc. Self-maintaining hot tub or spa
US12473529B2 (en) 2023-07-18 2025-11-18 Nanotein Technologies, Inc. Reagents, reagent kits, and culture media for activating and expanding immune cells and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2321687T3 (es) * 1999-11-15 2009-06-10 Innate Pharma Receptor activador implicado en la citotoxicidad natural mediada por las celulas destructoras naturales humanas y anticuerpos que identifican dicho receptor.
US6979546B2 (en) * 1999-11-15 2005-12-27 Universita Di Genova Triggering receptor involved in natural cytotoxicity mediated by human natural killer cells and antibodies that identify the same

Also Published As

Publication number Publication date
US20080063717A1 (en) 2008-03-13
AU2003294930B2 (en) 2008-12-04
AU2003294930A1 (en) 2004-07-14
JP2006514024A (ja) 2006-04-27
EP1575615A1 (en) 2005-09-21
WO2004056392A1 (en) 2004-07-08

Similar Documents

Publication Publication Date Title
CA2510787A1 (en) Pharmaceutical compositions having an effect on the proliferation of nk cells and a method using the same
JP7062720B2 (ja) 細胞免疫療法のための方法および組成物
AU2019203823B2 (en) CS1-specific chimeric antigen receptor engineered immune effector cells
Petersen et al. Improving T-cell expansion and function for adoptive T-cell therapy using ex vivo treatment with PI3Kδ inhibitors and VIP antagonists
JP7288405B2 (ja) ヒトドメインを有する抗ｂ細胞成熟抗原キメラ抗原受容体
EP3641768B1 (en) Chimeric Antigen Receptors (CARs), Compositions and Associated Methods
Phillips et al. Activation of natural killer cells via the p75 interleukin 2 receptor.
Revoltella et al. Granulocyte–macrophage colony-stimulating factor as an autocrine survival-growth factor in human gliomas
JP7447388B2 (ja) 感染性疾患の治療のための共受容体システム
JP2021078514A (ja) 血液系腫瘍を標的としたキメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法
WO2018229163A1 (en) Methods of activating v delta 2 negative gamma delta t cells
Li et al. rhIL-7-hyFc, a long-acting interleukin-7, improves efficacy of CAR-T cell therapy in solid tumors
US20060034767A1 (en) Targeting and tracking of cells to specific organs and tissues in vivo
Yang et al. A novel activation pathway for mature thymocytes. Costimulation of CD2 (T, p50) and CD28 (T, p44) induces autocrine interleukin 2/interleukin 2 receptor-mediated cell proliferation.
CN107531804A (zh) 嵌合蛋白
KR20210098940A (ko) Ebv 관련 암의 치료를 위한 항-lmp2 tcr-t 세포 요법
Howells et al. Peripheral blood lymphocytes express the platelet‐type thrombin receptor
WO1996014865A1 (en) Methods for inhibiting graft versus host disease in bone marrow transplantation
Sulica et al. Divergent effects of FcγRIIIA ligands on the functional activities of human natural killer cells in vitro
Harris et al. Modulation of function-associated molecules on natural killer cells alters recognition and cytotoxicity
KR20240095012A (ko) Cd137 세포외 도메인을 포함하는 융합단백질, 이를 발현하는 면역세포 및 이의 용도
JP2025540077A (ja) ナチュラルキラー細胞エンゲージャー
US20240207312A1 (en) Chimeric antigen receptor (car)-t cells
AU2999299A (en) Methods and compositions for the selective expansion of gamma/delta t-cells
Yamaguchi et al. Induction of negative regulators of haematopoiesis in human bone marrow cells by HLA-DR cross-linking

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead